THE EPIDEMIOLOGY OF TENOFOVIR-ASSOCIATED RENAL FAILURE IN PATIENTS ON ANTIRETROVIRAL THERAPY IN SWAZILAND

By
Dr Sithembile Dlamini
Student No.: 15132014

Submitted in partial fulfilment of the requirements for the degree
Master of Science MSc (Epidemiology)

in the
Faculty of Health Sciences
University of Pretoria

2018

Supervisor
Dr. NRT Ledibane

Co-supervisor
Dr. SG Takuva
DECLARATION OF AUTHORSHIP

“I declare that the dissertation, which I hereby submit for the degree Master of Science (Epidemiology) at the University of Pretoria, is my own work and has not previously been submitted by me for a degree at another University”.

Date of Approval from Research Ethics Committee
University of Pretoria: 24 November 2016

Reference number
University of Pretoria: 428/2016

Student Signature ___________________________ Date __20 November 2018_____

Supervisor Signature _________________________ Date __20 November 2018_____

Co-supervisor Signature ______________________ Date __20 November 2018_____

Name of Journal for Proposed Submission
Journal of the International AIDS Society (JAIDS)
ACKNOWLEDGEMENTS

Firstly, I would like to thank my Father, the Almighty God, for His endless provisions during my study period. I profoundly thank Him for His infinite grace and for carrying me through, especially during the trying times.

A deep appreciation goes to my supervisors, Dr Neo Ledibane and Dr Simbarashe Takuva, for their guidance and advice provided during the course of this study.

I express gratefulness to the Ministry of Health in Swaziland (Eswatini) and the management at Mbabane government hospital and Raleigh Fitkins hospital for granting me the permission to utilise the data for this research. I thank my colleagues, mentors and friends for the support during the study period.

I would like to thank my husband, Ayanda Nqeketo for the encouragement and support; and further extend my deepest gratitude to my son, Phikolomzi and daughter, Athenkosi for their kind consideration and indulgent understanding while I, as a mom, was busy with both work and studies and at times, had to be away from them at such young and tender ages. I remain entirely indebted with thankfulness to my entire extended family for their unwavering support, for always believing in me and daring behind me to realise my full potential.
ABSTRACT

**Background:** Tenofovir (TDF) forms part of the backbone of first and second line HIV infection management. There is limited data from resource-constrained settings on nephrotoxic adverse effects of Tenofovir based antiretroviral therapy (ART).

**Objective:** We investigated the incidence and risk factors of TDF-associated nephrotoxicity in a cohort of HIV-infected patients on either TDF or Zidovudine (AZT) based first line ART.

**Methods:** A retrospective analysis was conducted on a sample of participants initiated on first-line TDF- and Zidovudine (AZT)-based regimens between January 2010 and December 2015; from the national ART electronic database of Mbabane Government and Raleigh Fitkins Memorial hospitals in Swaziland. Time-to-onset of toxicity was assessed using Kaplan-Meier survival analysis and the log rank test was used to compare renal dysfunction by TDF or AZT first line regimen status. Toxicity incidence rate was calculated and multivariate Cox regression model was used to identify the potential risk factors.

**Main Findings:** A total of 1,119 participants with median age 36 years (IQR: 18 to 79 years), were included in the analysis 83% (n=929) on TDF and 17% on AZT (n=190). The median time to onset of toxicity was 6.72 months (IQR: 0.03 to 81.61). The overall incidence rate was 8.08 per 1000 person-months. TDF-associated nephrotoxicity was 9.44 per 1000 person-months (95% CI: 7.79 to 11.44) and 4.83 per 1000 person-months (95% CI: 3.18 to 7.33) for AZT. Participants on TDF-based regimen were more likely to develop toxicity in comparison to AZT, hazard ratio 2.08 (95% CI: 1.27 to 3.40, p=0.003). The mean CD4 count was 194 cells/µL (95% CI: 207.61 to 228.75), and mean eGFR was 123.56, (95% CI: 121.22 to 125.92). The co-variates: sex, age, WHO clinical staging, body mass index and CD4 cell count were not associated with developing nephrotoxicity (p>0.05).

**Conclusion:** Although TDF is effective in HIV management, it is associated with a two-fold increased risk of abnormal renal function during the follow-up period compared to those on AZT. This underlines the paramount importance of regular record-keeping for thorough pharmacovigilance and routine surveillance due to its wide usage.
**Key words:** Estimated Glomerular filtration rate (eGFR), Nephrotoxicity, Tenofovir (TDF), Zidovudine (AZT), Retrospective, Survival analysis, HIV cohort, Antiretroviral therapy (ART), Swaziland.
TABLE OF CONTENTS

DECLARATION OF AUTHORSHIP .................................................................................. i

ACKNOWLEDGEMENTS ............................................................................................... ii

ABSTRACT .................................................................................................................. iii

TABLE OF CONTENTS ................................................................................................... v

LIST OF TABLES ............................................................................................................ ix

LIST OF FIGURES ......................................................................................................... ix

ABBREVIATIONS .......................................................................................................... x

CHAPTER 1: INTRODUCTION ....................................................................................... 1

1. Background ................................................................................................................. 1

1.1 HIV Epidemiology in Swaziland (Eswatini) ............................................................. 1

1.2 The national HIV health sector response ............................................................... 1

1.3 National HIV Guidelines: Treatment Regimens ....................................................... 2

1.4 The research problem ............................................................................................... 4

1.5 Hypothesis ............................................................................................................... 4

1.6 Aim and objectives .................................................................................................. 5

1.6.1 Aim .................................................................................................................... 5

1.6.2 Primary Objectives ........................................................................................... 5

CHAPTER 2: LITERATURE REVIEW ............................................................................. 6

2.1 Introduction .............................................................................................................. 6

2.2 HIV-associated Nephropathy ................................................................................. 6

2.3 Tenofovir and its effects on the kidney ................................................................. 7

2.4 Risk factors for TDF nephrotoxicity ...................................................................... 8

2.5 The public health implications of TDF use .......................................................... 9
CHAPTER 3: METHODS

3.1 Study Design

3.2 Study Setting

3.3 Patient selection

3.3.1 Study Population

3.3.2 Patient selection/recruitment

3.3.3 Inclusion Criteria:

3.3.4 Exclusion Criteria

3.4 Definition of the Outcome

3.5 The main exposure variable

3.6 Measurements

3.7 Sampling Method

3.7.1 Sample size justification

3.8 Data analysis

3.8.1 Descriptive Analysis

3.8.2 Analysis by Objective

3.9 Ethical Considerations

CHAPTER 4: RESULTS

4.1 Descriptive analysis

4.2 Outcome variable definition

4.3 Overall follow-up time

4.4 Incidence rate

4.4.1 Incidence by outcome using abnormal renal function

4.4.2 Incidence by outcome using eGFR
4.5 Univariate analysis .................................................................................................................. 26
4.6 Multivariate Analysis .............................................................................................................. 27

CHAPTER 5: DISCUSSION ............................................................................................................. 28
5.1 Descriptive Analysis .............................................................................................................. 28
5.2 Overall follow-up time ......................................................................................................... 28
5.3 Incidence rate of abnormal eGFR ....................................................................................... 29
5.4 Risk factors associated with Tenofovir associated renal dysfunction ......................... 30
5.5 Economic estimation of the cost of reversing the TDF associated renal dysfunction ... 30
5.6 HIV and HBV co-infection .................................................................................................. 31
  5.6.1 Tenofovir Alafenamide ................................................................................................. 31

CHAPTER 6: STRENGTHS AND WEAKNESSES (LIMITATIONS) ........................................... 33
6.1 Strengths ............................................................................................................................. 33
  6.1.1 .......................................................................................................................................... 33
  6.1.2 .......................................................................................................................................... 33
  6.2.3 .......................................................................................................................................... 33
6.2 Limitations ............................................................................................................................ 33

CHAPTER 7: CONCLUSION AND RECOMMENDATIONS ....................................................... 35
7.1 Tenofovir Alafenamide (TAF) ............................................................................................ 35
7.2 Database redesign ................................................................................................................. 35
7.3 Review of HIV Management Guidelines ........................................................................... 36
7.4 Further Research .................................................................................................................. 36

REFERENCES ............................................................................................................................ 37

ANNEXES ..................................................................................................................................... 43
Annex 1: Permission to access records approval .................................................................... 43
Annex 2: Data collection form: TDF associated nephrotoxicity and risk factors .................45

Annex 3: Ethical approval reference no: 428/2016 .................................................................47

Annex 4: Ethical approval reference no: 428/2016 for amendment of protocol .................48
LIST OF TABLES

Table 1: Percentage of Adults (15+ years) on first line ART Regimen and second line ART regimen, 2016 ................................................................. 3
Table 2: Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1, July 2017 ................................................................. 13
Table 3: Chronic Kidney Disease Classification ........................................................................ 14
Table 4: Definitions of the Demographic and Clinical variables ............................................. 15
Table 5: Sample size estimation for varying hazard ratio......................................................... 17
Table 6: Descriptive analysis of participants on ART initiation of TDF-based and AZT-based regimen at MGH and RFM hospitals, 2010-2015 ................................................................. 21
Table 7: The univariate analysis by covariates: sex, age, WHO stage, BMI, CD4 cell count .... 26
Table 8: The multivariate analysis by covariates: sex, age, WHO stage, BMI, CD4 cell count 27

LIST OF FIGURES

Figure 1: Swaziland HIV Management Guidelines - ART Regimen: 2015 ................................. 3
Figure 2: Map of Swaziland ..................................................................................................... 10
Figure 3: Flow diagram of study Participants at MGH and RFM hospital, 2010-2015 ............... 20
Figure 4: Kaplan-Meier curve: overall follow-up time (months) .............................................. 23
Figure 5: Kaplan-Meier curve and Log-rank test for main exposure (TDF versus AZT), by abnormal renal function (creatinine) of study Participants at MGH and RFM hospital, 2010-2015 ......................................................................................................................... 24
Figure 6: Kaplan-Meier curves and Log-rank test for main exposure (TDF versus AZT) by abnormal eGFR of study Participants at MGH and RFM hospital, 2010-2015 ......................... 25
ABBREVIATIONS

3TC  Lamivudine
ABC  Abacavir
AIDS Acquired Immuno-deficiency syndrome
ART  Antiretroviral therapy
ARV  Anti-retroviral
ATI  Acute tubular injury
ATV/r Atazanavir boosted with Ritonavir
AZT  Zidovudine
CKD  Chronic Kidney Disease
CrCl Creatinine Clearance
D4T  Stavudine
DSD  Differentiated Service Delivery
EFV  Efavirenz
eGFR Estimated Glomerular filtration rate
FDC  Fixed dose combination
HBV  Hepatitis B virus
HIV  Human Immunodeficiency Virus
LPV/r Lopinavir boosted with Ritonavir
MDRD Modification of Diet in Renal Disease
MGH  Mbabane Government Hospital
NRTI  Nucleoside Reverse Transcriptase Inhibitor
NtRTI Nucleotide analogue reverse-transcriptase inhibitor
NVP  Nevirapine
PLHIV People Living with HIV
RFM  Raleigh Fitkins Memorial Hospital
RNA  Ribonucleic acid,
SD  Standard deviation
SDHS Swaziland Demographic Health Survey
SNAP Swaziland National AIDS program
SZL  Emalangeni
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAF</td>
<td>Tenofovir alafenamide</td>
</tr>
<tr>
<td>TDF</td>
<td>Tenofovir Disoproxil Fumarate</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>ZAR</td>
<td>South African Rand</td>
</tr>
</tbody>
</table>
CHAPTER 1: INTRODUCTION

1. Background

1.1 HIV Epidemiology in Swaziland (Eswatini)

Swaziland (Eswatini) is a landlocked country in Southern Africa, bordered to the North, South and West by South Africa, and to the East by Mozambique. It is divided into four regions: Hhohho, Manzini, Shiselweni and Lubombo. Communicable diseases contribute the largest portion of the burden of disease in Swaziland.\(^{(1)}\)

Swaziland has a generalised HIV epidemic, with the highest HIV prevalence in the world.\(^{(1)}\) New HIV infections are declining and the incidence rate among adults aged 18-49 years is estimated at 1.4%, comprising 1.0% and 1.7% of men and women, respectively. New HIV infections have reduced by about 44% in five years since 2011. According to the Swaziland HIV Incidence Measurement Survey 2016/17, the HIV prevalence shows an increase with age for both sexes, reaching the peak earlier for women (35-39 years; 54.2%) than men (45-49 years; 48.8%).

The disproportion in prevalence by sex is most pronounced among adolescents and young people with 20-24 year old females having a five times higher prevalence (20.9%) than males (4.2%).\(^{(2)}\) The UNAIDS estimated that in 2017, 210'000 adults and children in Swaziland were living with HIV and 3500 deaths were AIDS-related. \(^{(3)}\)

1.2 The national HIV health sector response

In an effort to combat the high burden of HIV and AIDS, the government of Swaziland established the Swaziland National AIDS Program (SNAP) in 1987 to respond to the HIV epidemic.\(^{(4)}\) The HIV programme is mandated to coordinate the health sector interventions. SNAP aims to ensure that all people living with HIV (PLHIV) are provided with appropriate health services which improve health outcomes, reducing the morbidity and mortality rates, through decentralisation.
The provision of decentralised HIV testing services (HTS) and antiretroviral therapy (ART) services, within the public and private sectors, has expanded rapidly over the last ten years to reach remotest of rural clinics in the country, using the primary health care approach. Decentralisation of ART services to lower level clinics has been a very important strategy in the HIV response in the country. This has ensured that the majority of the population living in the rural areas (approximately 70%) have access to the HIV treatment services, without suffering massive expenditure due to accessing essential health services.\(^4\)

Currently more than 80% of the public health facilities are accredited to provide ART services and more than 60% of the ART initiations in the country are done by nurses who have been trained on ART initiation following the National HIV guidelines.\(^4\) To further expand decentralised ART services, the country introduced the differentiated service delivery (DSD) model which extends ART services into the community. This model is also aimed at addressing the barriers to HIV care linkage and poor retention rates over time.\(^5\) At the end of 2017, the ART coverage in Swaziland was 85% among People Living with HIV (PLHIV), comprising 75% and 86% for children less than 15 years and adults older than 15 years, respectively.\(^6\)

### 1.3 National HIV Guidelines: Treatment Regimens

The Swaziland Ministry of Health closely follows the World Health Organization (WHO) recommendations including guidelines for ART and has adopted a homogeneous first line therapy with Tenofovir disoproxil fumarate (hereafter referred to as “Tenofovir,” and denoted as TDF) for adolescents and adults. Swaziland adopted the 2016 WHO HIV ‘Test and Treat all’ guidance, hence more people living with HIV were eligible and enrolled on a TDF-based regimen.\(^7\)

At the time of this study, SNAP was using the 2010 WHO HIV guidelines recommendations for the management of ART eligible patients. The National HIV guidelines recommended the use of TDF (Tenofovir) + 3TC (Lamivudine) + EFV (Efavirenz) as a fixed-dose combination (FDC) to enable ease of administration, as well as to encourage and promote adherence. Since then, Tenofovir has been used as part of the first line and second line ART regimens in Swaziland for the management of HIV infection in adolescents and adults.\(^8\)
The first line option was recommended for all HIV-infected eligible adolescents and adults who were treatment naïve patients, unless contraindicated, in which case the alternative regimens were offered as shown in Figure 1. In Swaziland, TDF is limited to the management of HIV. Patients co-infected with HIV and hepatitis B virus (HBV), benefit from the ART to manage and control the HBV infection. During the study period, the country did not have clinical guidelines for the management of HBV.

The 2015 Swaziland national guidelines indicate EFV as a contraindication in patients with moderate to severe EFV-induced skin reaction, severe mental illness (e.g. depression, psychosis) and bilateral gynaecomastia in males.\(^{(9)}\)

<table>
<thead>
<tr>
<th>First Line Regimen</th>
<th>Second line regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 TDF + 3TC + EFV</td>
<td>1. AZT + 3TC + LPV/r</td>
</tr>
<tr>
<td>2 TDF + 3TC + NVP</td>
<td>2. TDF + 3TC + LPV/r</td>
</tr>
<tr>
<td>3 AZT + 3TC + EFV</td>
<td></td>
</tr>
<tr>
<td>4 AZT + 3TC + NVP</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1: Swaziland HIV Management Guidelines - ART Regimen: 2015
(SOURCE: Swaziland integrated Comprehensive HIV Management guidelines, 2015: page 86)

At the end of 2016, the ART coverage was 77% (149,160 of 193,715) of total number of adolescents and adults aged 15 years and older living with HIV and were eligible for ART based on guidelines at that time. The 2016 Ministry of Health annual HIV program report stated that at least 67% of adult and adolescent (above 15 years of age) patients who were active on first line ART were on a TDF-based ARV triple therapy and at least 29% of those were on a second line regimen. Table 1 shows the regimen breakdown.\(^{(10)}\)

Table 1: Percentage of Adults (15+ years) on first line ART Regimen and second line ART regimen, 2016

<table>
<thead>
<tr>
<th>FIRST LINE REGIMEN - Percent</th>
<th>SECOND LINE REGIMEN- Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDF+3TC+EFV - 64%</td>
<td>ABC+3TC+LPV/r - 32%</td>
</tr>
<tr>
<td>AZT+3TC+NVP - 19%</td>
<td>TDF+3TC+LPV/r - 29%</td>
</tr>
<tr>
<td>D4T+3TC+NVP - 6%</td>
<td>AZT+3TC+LPV/r - 23%</td>
</tr>
<tr>
<td>AZT+3TC+EFV - 6%</td>
<td>D4T+3TC+LPV/r - 6%</td>
</tr>
<tr>
<td>TDF+3TC+NVP - 3%</td>
<td>ABC+DDI+LPV/r - 3%</td>
</tr>
<tr>
<td>Other - 2%</td>
<td>Other - 7%</td>
</tr>
<tr>
<td>TOTAL= 149 160 (100%)</td>
<td>TOTAL= 784 (100%)</td>
</tr>
</tbody>
</table>

Source: Annual HIV report, Source: HMIS 2016
1.4 The research problem

A significant number, although unquantified and undocumented, of patients in Swaziland who are initiated on a TDF-based triple regimen are at risk of developing TDF nephrotoxicity. Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI) and indicated as part of the first line antiretroviral therapy (ART) for the management of HIV infection. Despite normal renal function test results at baseline, some patients develop renal dysfunction with treatment progression. Those with renal failure have to undergo renal dialysis, and prompt substitution of TDF with another NRTI drug.

In certain instances, the renal dysfunction or renal failure is reversible after commencing renal dialysis and TDF substitution. The onset, incidence and the economic impact of the TDF-associated toxicity are unknown in the Manzini and Hhohho regions. The risk factors are documented in literature as uncommon.\(^\text{(11)}\)

In Swaziland, this information is undocumented, therefore, this remains a concern as nearly 70% of ART eligible HIV-infected patients were on a TDF-based first line triple regimen and about 30% of patients on second line were on a TDF-based regimen, in 2016.\(^\text{(10)}\)

In 2017 Swaziland adopted and implemented the 2016 WHO “Test and Treat all” HIV treatment guidelines. The guidelines recommend the use of TDF in first and second line ART regimens.\(^\text{(7)}\) It is therefore imperative to document the incidence of TDF-associated renal pathology as the implementation is at a national scale to enable comprehension of the magnitude of this health problem. The information on the incidence, the onset and risk factors of the TDF-associated renal failure is not available in Swaziland. Such information needs to be readily available since TDF forms part of the backbone of both first and second line therapy for the management of HIV infection.

1.5 Hypothesis

The null hypothesis (H\(_0\)): There is no difference in the risk of developing TDF-associated renal failure on first line ART regimen when comparing TDF+3TC+EFV/NVP and AZT+3TC+EFV/NVP.
The alternate hypothesis ($H_a$): There is a risk of developing TDF-associated renal failure on first line ART regimen when comparing TDF+3TC+EFV/NVP and AZT+3TC+EFV/NVP.

1.6 Aim and objectives

1.6.1 Aim

The aim of the study was to understand the epidemiology of TDF-associated renal failure of HIV-infected patients initiated on ART regimens at treatment centres: Raleigh Fitkin Memorial (RFM), a regional referral hospital and Mbabane government hospital (MGH), the national referral hospital; in Swaziland from January 2010 to December 2015.

1.6.2 Primary Objectives

1. To estimate the incidence of TDF-associated renal failure in patients on standard ART regimens.
2. To examine the association between ART regimen and renal failure among patients on standard first line and second line ART regimens.
3. To examine the risk factors for renal failure among patients using first and second line regimens.
2.1 Introduction

The Swaziland national HIV management guidelines recommend that each patient must have baseline blood results of the following tests prior to commencing treatment; CD4 cell count, renal function, liver function and full blood count. Patients initiated on TDF are those assessed as having a normal range of baseline renal function tests including a calculated creatinine clearance for all patients prior to TDF initiation. The guidelines further state that patients with and/or at risk of renal disease (those with known underlying renal disease, older than 50 years, low BMI < 18.5kg/m², diabetes mellitus, hypertension and patients on nephrotoxic drugs) should be managed with caution.\(^\text{(12)}\)

The recommended post-ART initiation clinical monitoring intervals are at two weeks, then at four to eight weeks.\(^\text{(9)}\) Follow-up visits are increased to every two months if patients do not have complications and are stable on ART. The routine laboratory monitoring include renal function test, liver function test and full blood count as well as the CD4 cell count at least every six months and a viral load at month six of ART initiation, then annually thereafter.

In instances where the blood results are deranged, more intensive patient-specific follow-up and monitoring is instituted.\(^\text{(9)}\) The clinic visits are documented, including any drug adverse events/toxicities experienced related to the ART regimen taken by the patient. The adverse events are recorded and reported as part of the pharmacovigilance activities.

2.2 HIV-associated Nephropathy

Nephropathy is documented as a relatively common complication in patients infected with HIV.\(^\text{(12)}\) The HIV nephropathy could be a result of direct HIV infection of the kidney epithelial cells or from the adverse effects of antiretroviral drugs. The natural course of the HIV disease without ART (HIV-associated nephropathy), is characterised by rapid progression to renal failure and end-stage renal disease leading to the need for dialysis.\(^\text{(13,14)}\) The introduction of ART in HIV management has changed the natural course of HIV renal disease and has significantly slowed this disease progression.\(^\text{(11)}\)
2.3 Tenofovir and its effects on the kidney

Tenofovir (TDF) is a nucleotide reverse transcriptase inhibitor (NtRTI) and indicated for the management of HIV and Hepatitis B virus infection. One of the documented side-effects is nephrotoxicity which could progress to renal failure. TDF is an orally bioavailable prodrug of Tenofovir, an acyclic nucleotide analogue NRTI. The proximal tubular cell is the main target for Tenofovir toxicity due to its complement of cell membrane transporters which favour its accumulation.\(^4\)

TDF nephrotoxicity is characterised by proximal tubular cell dysfunction which may be associated with acute kidney injury or chronic kidney disease.\(^{15}\) Studies have demonstrated that tubular dysfunction occurs in 17–22% of Tenofovir-treated patients, versus 6 and 12% of other ART-treated or naive HIV patients.\(^{8,11}\)

TDF is eliminated unchanged in the urine by a combination of glomerular filtration and proximal tubular secretion.\(^{14}\) Drug transporters expressed in renal proximal tubule cells are believed to influence Tenofovir plasma concentration and toxicity in the kidney.\(^{16}\) About 20–30% of the drug is actively transported into renal proximal tubule cells by organic anion transporters in the basolateral membrane.\(^{10,11}\)

Despite this, the general safety profile of TDF is good and the majority of patients tolerate the drug reasonably well.\(^{13}\) The most effective treatment of TDF nephrotoxicity is stopping TDF and this often results in clinical improvement of kidney injury, which may be partial. The prevention of TDF-induced nephrotoxicity requires careful monitoring.\(^{17,18}\)

It is expected that once TDF is stopped renal recovery should be quicker than the renal function decline.\(^{19}\) However a study conducted in 2012 in the United States Veterans Health Administration, concluded that the exposure to TDF was independently associated with increased risk of kidney disease events, and did not appear to be reversible.\(^{13}\)
2.4 Risk factors for TDF nephrotoxicity

Several risk factors which predispose patients to develop the TDF-induced nephrotoxicity are known and documented.\textsuperscript{(14)} Post-marketing clinical data showed that advanced age, low body weight, higher serum creatinine levels before starting TDF treatment, comorbidities (diabetes, hypertension) concomitant nephrotoxic medications, advanced HIV infection (low CD4 cell count, AIDS), and, in some studies, male sex were risk factors for TDF-induced glomerular filtration rate (GFR) reduction.\textsuperscript{(13,14,17,20)}

Some studies have reported the dominant contributors to the chronic kidney disease (CKD) risk score as the traditional kidney disease risk factors (age, glucose, systolic hypertension, triglycerides, and proteinuria). The overall 5-year event rate was 7.7% in TDF users.\textsuperscript{(12)(19)}

The Swaziland Ministry of Health’s 2016 first quarter pharmacovigilance newsletter stated that 81% of 398 reported adverse events were from patients on the TDF+3TC+EFV regimen and 150 of these adverse events were classified as severe to life-threatening or death, 5% of these serious adverse events were TDF-associated renal failure.\textsuperscript{(21)} The report was based on 7 sentinel sites out of the 133 health facilities which offer ART services. It is estimated and projected that this complication develops in approximately 15% of patients on a TDF-based regimen, nationally in Swaziland.\textsuperscript{(21)}

When renal failure is diagnosed at routine clinical monitoring, the patients are referred to one of the two dialysis units in Swaziland. The dialysis is commenced together with the substitution of TDF by another NRTI, Zidovudine (AZT) or Abacavir (ABC).

Renal dysfunction and/or failure develops despite normal renal function before ART initiation. In some cases the renal dysfunction/failure is reversible and irreversible in others. These outcomes are not documented in Swaziland. The development of renal failure poses a serious threat and a potentially life-threatening risk to the patient, and furthermore increases the demand and cost of dialysis on an already constrained and overstretched health system.
2.5 The public health implications of TDF use

The above-mentioned studies together with numerous other studies have demonstrated the advantages of the use of TDF as part of the ART regimen. The potential TDF-associated nephrotoxicity is not an impediment to its widespread use in the treatment of HIV infection, since the drug is well tolerated by the majority of patients.\(^{[22]}\) The World Health Organization also continues to recommend TDF for the treatment of HIV, as well as for the prevention of HIV as pre-exposure prophylaxis. The Ministry of Health in Swaziland thus far is compelled by the available evidence to continue to use TDF in the ART regimen.

As the global price decreases annually it becomes even cheaper and more cost-effective to enrol patients on TDF-based regimen. However, renal toxicity poses higher risks in resource-limited settings, where routine laboratory monitoring is somewhat limited and death from acute renal failure may even approach 90%.\(^{[20]}\)

The Swaziland National AIDS Program (SNAP) needs to continually ensure access to laboratory monitoring services for all patients; as well as assisting with the advocacy, forecasting and quantification of renal function tests laboratory reagents. This enables and ensures accurate patient monitoring and appropriate management.
CHAPTER 3: METHODS

3.1 Study Design

The study employed a retrospective cohort study design. The data were collected as secondary data from electronic medical records using a standardised tool (Annex 2).

3.2 Study Setting

The study setting was the ART clinics of Raleigh Fitkin Memorial hospital (RFM), a regional referral hospital, and Mbabane Government (MGH) hospital, a national referral hospital. MGH is located in Mbabane, the capital city of Swaziland, within the Hhohho region. RFM is located in the Manzini region, the largest city and economic hub of Swaziland. RFM is a mission hospital which receives funding through the Swaziland government subvention.

![Map of Swaziland](image)

**Figure 2: Map of Swaziland**

Source: Makhoselive Dlamini, WHO Geographic Information System Analyst - 12 February 2018, Mbabane, Swaziland
These hospitals are both public sector hospitals and located in the two largest and most populated urban cities and regions of Swaziland. MGH and RFM serve primary health clinics and smaller hospitals called health centres, which in turn refer patients to the two hospitals in the respective regions. Additionally, MGH also serves as the national referral hospital for all regional hospitals, including RFM.

The two hospitals are serviced by specialists, medical officers and nurses; and both have renal units which offer dialysis services in the respective regions for all the referred patients. The MGH ART clinic is serviced by medical officers, nurses and lay cadres while the renal unit is serviced by general medical officers, internal medicine physicians and a nephrologist. The RFM ART clinic is serviced by general medical officers, nurses and lay cadres and the renal unit is serviced by medical officers, an anesthesiologist and a visiting nephrologist, who reviews complicated cases on a weekly basis.

The two hospitals are financially supported by the Swaziland government through the Ministry of Health. The HIV commodities and antiretroviral medicines are all procured and distributed by the central medical stores of the Ministry of Health. In both hospitals, HIV services including HIV treatment are offered at no cost to the patient.

3.3 Patient selection

3.3.1 Study Population

The study population comprised all the HIV-infected patients initiated on a TDF-based standard regimen between January 2010 and December 2015. TDF was first available and used in Swaziland in 2010, for patients aged 18 years and older at the two hospitals.

3.3.2 Patient selection/recruitment

The study participants’ data were extracted from the national ART electronic database for Mbabane Government Hospital and Raleigh Fitkin Memorial Hospital. The sampling frame comprised all HIV-infected patients initiated on ART from January 2010 to December 2015, listed on the national electronic ART database for the two hospitals. The data were then filtered according to the inclusion and exclusion criteria as listed below:
3.3.3 Inclusion Criteria:

- HIV-infected patients, aged 18 years and above
- HIV-infected patients to be on a TDF or AZT-based regimen (between 01 January 2010 and 31 December 2015)
- HIV-infected patients with all baseline and follow-up creatinine blood results

3.3.4 Exclusion Criteria

- HIV-infected patients aged less than 18 years
- Patients taking TDF for viral Hepatitis B infection only
- Patient medical records with no baseline and follow-up creatinine blood results

The study used secondary data from the national data base captured from the ART medical clinical records. A standard data collection form (Annex 2) which included all the variables of interest was used to abstract the data. The demographic and clinical variables at baseline and follow-up were recorded. The pregnancy status of the female participants was disregarded.

The following variables were considered and measured. Demographic variables: age in years at last birthday during ART initiation, sex, health facility, date of ART initiation and date of current ART regimen. Clinical variables: body mass index (BMI=weight (kg)/height (m)^2), WHO clinical (Annex 5) stage at initiation, last WHO clinical stage while on ART, CD4 cell count (cells/µL) at initiation of ART, the last CD4 cell count, the last serum creatinine taken before the close of the study period, and the estimated glomerular filtration rate (eGFR) calculated for each participant using serum creatinine result.

3.4 Definition of the Outcome

The outcome variable of interest was TDF-associated renal dysfunction (including failure). In this study, it was measured as a proxy by looking at the study participants who had their start ART regimen modified from a TDF-based ART regimen to either an AZT- or ABC-based regimen. Renal dysfunction was defined as per the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1, July 2017 (Table 2); using the parameters: Creatinine, High and Creatinine Clearance or eGFR, Low.\(^{(19)}\)
### Table 2: Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1, July 2017

<table>
<thead>
<tr>
<th>PARAMETER</th>
<th>GRADE 1 (MILD)</th>
<th>GRADE 2 (MODERATE)</th>
<th>GRADE 3 (SEVERE)</th>
<th>GRADE 4 (POTENTIALLY LIFE-THREATENING)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium, High (mg/dL, mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 7 days of age</td>
<td>10.6 to &lt; 11.5, 2.65 to &lt; 2.85</td>
<td>11.5 to &lt; 12.5, 2.88 to &lt; 3.13</td>
<td>12.5 to &lt; 13.5, 3.13 to &lt; 3.38</td>
<td>≥ 13.5, ≥ 3.38</td>
</tr>
<tr>
<td>&lt; 7 days of age</td>
<td>11.5 to &lt; 12.4, 2.88 to &lt; 3.10</td>
<td>12.4 to &lt; 12.9, 3.10 to &lt; 3.23</td>
<td>12.9 to &lt; 13.5, 3.23 to &lt; 3.38</td>
<td>≥ 13.5, ≥ 3.38</td>
</tr>
<tr>
<td>Calcium (Ionized), High (mg/dL, mmol/L)</td>
<td>≤ ULN to ≤ 0.6, ≤ ULN to ≤ 1.5</td>
<td>0.6 to &lt; 1.6, ≤ 4.0</td>
<td>1.6 to &lt; 2.4, ≤ 7.2</td>
<td>≥ 1.8</td>
</tr>
<tr>
<td>Calcium, Low (mg/dL, mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 7 days of age</td>
<td>7.8 to &lt; 8.4, 1.95 to &lt; 2.10</td>
<td>7.0 to &lt; 7.8, 1.75 to &lt; 1.95</td>
<td>6.1 to &lt; 7.0, 1.53 to &lt; 1.75</td>
<td>≤ 6.1, ≤ 1.53</td>
</tr>
<tr>
<td>&lt; 7 days of age</td>
<td>6.5 to &lt; 7.5, 1.63 to &lt; 1.88</td>
<td>6.0 to &lt; 6.5, 1.30 to &lt; 1.63</td>
<td>5.50 to &lt; 6.0, 1.38 to &lt; 1.50</td>
<td>≤ 5.50, ≤ 1.50</td>
</tr>
<tr>
<td>Calcium (Ionized), Low (mg/dL, mmol/L)</td>
<td>≤ LLN to ≤ 4.0, ≤ LLN to ≤ 1.0</td>
<td>3.6 to &lt; 4.0, ≤ 0.9 to ≤ 1.0</td>
<td>3.2 to &lt; 3.6, ≤ 0.8 to ≤ 0.9</td>
<td>≤ 3.2, ≤ 0.8</td>
</tr>
<tr>
<td>Cardiac Troponin I, High</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Levels consistent with myocardial infarction or unstable angina as defined by the local laboratory</td>
</tr>
<tr>
<td>Creatinine, High</td>
<td>3.0 to ≤ 6 x ULN</td>
<td>&gt; 1.3 to ≤ 1.8 x ULN</td>
<td>&gt; 1.8 to ≤ 3.5 x ULN OR Increase to 1.3 to &lt; 1.5 x participant’s baseline</td>
<td>≥ 3.5 x ULN OR Increase of ≥ 20 x participant’s baseline</td>
</tr>
<tr>
<td>*Report only one</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine Clearance or eGFR, Low</td>
<td>NA</td>
<td>&lt; 90 to 60 ml/min or ml/min/1.73 m²</td>
<td>&lt; 60 to 30 ml/min or ml/min/1.73 m²</td>
<td>&lt; 30 ml/min or ml/min/1.73 m² OR ≥ 50% decrease from participant’s baseline or dialysis needed</td>
</tr>
<tr>
<td>*Report only one</td>
<td></td>
<td>OR 10 to ≤ 30% decrease from participant’s baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (mg/dL, mmol/L)</td>
<td>110 to 125, 6.11 to 6.93</td>
<td>&gt; 125 to ≤ 250, 6.95 to ≤ 13.89</td>
<td>&gt; 250 to ≤ 500, 13.89 to ≤ 27.75</td>
<td>≥ 500, ≥ 27.75</td>
</tr>
<tr>
<td>Fasting, High</td>
<td>116 to 160, 6.44 to 8.89</td>
<td>&gt; 160 to ≤ 250, 8.89 to ≤ 13.89</td>
<td>&gt; 250 to ≤ 500, 13.89 to ≤ 27.75</td>
<td>≥ 500, ≥ 27.75</td>
</tr>
<tr>
<td>Nonfasting, High</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

14 Use the applicable formula (i.e., Cockcroft-Gault in mL/min or Schwartz, MDRD, CKD-Epi in mL/min/1.73 m²). Sites should choose the method defined in their study and when not specified, use the method most relevant to the study population.

*Reminder: Choose the method that selects for the higher grade.

DAIDS AE Grading Table Corrected Version 2.1- July 2017

Page 28
The eGFR or creatinine clearance was estimated using the glomerular filtration rate (GFR) for each study participant using the Modification of Diet in Renal Disease (MDRD) formula;

\[ \text{GFR (mL/min/1.73m}^2\text{)} = 175 \times (\text{Scr})^{-1.154} \times (\text{Age})^{-0.203} \times (0.742 \text{ if female}) \times (1.212 \text{ black ethnicity}) \]

The required variables: creatinine, age, ethnicity and sex were available from the medical records database. Swaziland population is predominantly of black ethnicity. This formula has been validated extensively and has shown good performance for patients with all common causes of kidney disease.\(^{(23)}\) A study conducted in South Africa also validated the formula.\(^{(24)}\) Renal dysfunction was defined as an abnormal GFR or creatinine clearance of at least moderate severity (i.e. moderate, severe or potentially life-threatening severity).\(^{(19)}\)

3.5 The main exposure variable

The exposure variable is TDF, which is the drug of choice for ART naïve patients and patients who fail on first line AZT based regimen and have to be switched to second line ART regimen. The national HIV treatment guidelines indicate that if patients experience TDF-induced nephrotoxicity on routine clinical monitoring, they must be substituted to an alternative drug, either AZT or ABC, provided there is no clinical evidence of treatment failure.

In this study renal dysfunction and renal failure was graded according to the chronic kidney disease classification of renal dysfunction as shown below:

<table>
<thead>
<tr>
<th>Stage</th>
<th>GFR (mL/min/1.73m(^2))</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (nil or ↑GFR)</td>
<td>≥90</td>
</tr>
<tr>
<td>2 (mild ↓GFR)</td>
<td>60 - 89</td>
</tr>
<tr>
<td>3 (moderate ↓GFR)</td>
<td>30 - 59</td>
</tr>
<tr>
<td>4 (severe ↓GFR)</td>
<td>15 - 29</td>
</tr>
<tr>
<td>5 (kidney failure)</td>
<td>&lt;15 or dialysis</td>
</tr>
</tbody>
</table>

3.6 Measurements

The data were extracted from the national database of the two hospitals (MGH and RFM) and transcribed onto Microsoft Excel spreadsheet. They were secured with a password for restricted access, and backed up on a safely-store external hard drive. Table 4 below shows the measured of variables.

**Table 4: Definitions of the Demographic and Clinical variables**

<table>
<thead>
<tr>
<th>Demographic variable</th>
<th>Variable definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Age in years during ART initiation at last birthday</td>
</tr>
<tr>
<td>Sex</td>
<td>Male or Female</td>
</tr>
<tr>
<td>Health Facility Cluster</td>
<td>Mbabane Government Hospital/Raleigh Fitkin Memorial Hospital</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical variable</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>Body Mass Index (weight/height^2) at ART initiation</td>
</tr>
<tr>
<td></td>
<td>Underweight &lt; 18.5 kg/m^2</td>
</tr>
<tr>
<td></td>
<td>Normal- 18.5 – 24.9 kg/m^2</td>
</tr>
<tr>
<td></td>
<td>Overweight 25-30 kg/m^2</td>
</tr>
<tr>
<td></td>
<td>Obese- &gt;30 kg/m^2</td>
</tr>
<tr>
<td>WHO Clinical Stage(25)</td>
<td>Clinical stage of HIV clinical disease according to the World Health Organization classification at ART initiation (WHO clinical stage I; WHO clinical Stage II; WHO clinical Stage III; WHO clinical Stage IV)</td>
</tr>
<tr>
<td>Baseline CD4 cell count</td>
<td>CD4 cell count at initiation of ART and the last CD4 result before 31st December 2015</td>
</tr>
<tr>
<td></td>
<td>&lt;100 cells/µL; 100-199 cells/ µL</td>
</tr>
<tr>
<td></td>
<td>200-349 cells/ µL; ≥ 350 cells/ µL</td>
</tr>
<tr>
<td>Date of ART Initiation</td>
<td>dd/mm/yyyy</td>
</tr>
<tr>
<td>Start ART regimen</td>
<td>The ARV combination (regimen) at ART initiation</td>
</tr>
<tr>
<td>Date of current ART regimen</td>
<td>Date of last ART regimen change</td>
</tr>
<tr>
<td>Current ART Regimen</td>
<td>The ARV combination (regimen) at the end of December 2015</td>
</tr>
<tr>
<td>Serum Creatinine (µmol/L)</td>
<td>The baseline and last recorded serum creatinine in the electronic file</td>
</tr>
<tr>
<td>estimated glomerular filtration rate(eGFR)</td>
<td>eGFR (mL/min/1.73m^2): measure of the renal function, calculated using serum creatinine, and graded as follows: Stage 1 (nil)≥90; Stage 2 (mild)=60-89; Stage 3 (moderate)=30-59; Stage 4 (severe)=15-29; Stage 5 (kidney failure)≤15</td>
</tr>
</tbody>
</table>
3.7 Sampling Method

A total of 65,178 ART patients who were on ART between January 2010 and December 2015, aged 18 years and older and listed on the national electronic ART database, comprised the sampling frame. Of these, 65% were from Manzini and Hhohho regions. Systematic random sampling was used to eliminate subjectivity and minimize bias.

A computer-generated random number, 4, was selected using Microsoft Excel 2013. Every 4th patient file was selected from the Mbabane Government Hospital and Raleigh Fitkin Memorial Hospital database until there were 593 patient files from each hospital as per the calculated sample size. This gave the total study a sample size of 1186 study participants, of whom 82.9% (n=983) were on TDF and 17.1% (n=203) were on AZT. The distribution by gender; 61.8% (n=733) were female and 38.3% (n=453) were male.

3.7.1 Sample size justification

The sample size was estimated for the main study objective – To examine the impact of TDF versus AZT regimen on the risk of renal failure among patients on standard first line and second line ART regimens. In reference to the data of Scherzer, Estrella, Lia et al. (13), the survival analysis sample size estimation involving comparisons between groups was done using the log-rank test which requires estimates of hazards of the two groups of primary comparisons.

The majority (80%) of patients in the Swaziland ART database are on a TDF based regimen. The hazard ratio for progression to renal derangement among those on TDF compared to those on AZT ranged from 1.25 to 2.50. (13)(26)

Using the statistical package, STATA version 13, the sample size calculation for the log-rank test; assuming a 5% level of significance, the use of a two-sided test in the analysis and 20% prevalence of those on AZT based regimen and hazards ratio of renal derangement of between 1.25 and 2.50; Table 5 presents estimated minimum power for the different scenarios using the estimated sample size of 1120; and thus a robust enough power (at least 80%) to detect HR of at least between 1.25 and 2.50.
Table 5: Sample size estimation for varying hazard ratio

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Hazard ratio</th>
<th>1.25</th>
<th>1.30</th>
<th>2.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>1120</td>
<td>1120</td>
<td>1120</td>
<td></td>
</tr>
<tr>
<td>Level of significance</td>
<td>5%</td>
<td>5%</td>
<td>5%</td>
<td></td>
</tr>
<tr>
<td>Power</td>
<td>80%</td>
<td>89%</td>
<td>&gt;99%</td>
<td></td>
</tr>
</tbody>
</table>

3.8 Data analysis

The data were transcribed on the Microsoft Excel 2013 spreadsheet, and then checked for accuracy, completeness, consistency and cleaned through inspection and correction of errors and extreme outliers prior to analysis and then exported to STATA version 13 (STATA Corp, 2014, College Station, Texas, USA) for analysis.

3.8.1 Descriptive Analysis

Descriptive statistics were used to summarise the data. For categorical data, frequency distribution tables were used to summarise data using numbers and percentages. The analysis of numerical and continuous data depended on the distribution of data, which were assessed using the histogram and normality tests. Numerical data which assumed normal distribution were summarised using the mean as the measure of central tendency and the standard deviation (SD) as the measure of variation. For skewed data, the median was used as a measure for central tendency and the inter-quartile range (IQR) as a measure of variation.

3.8.2 Analysis by Objective

Further analysis was done using Kaplan-Meier survival curves and the log-rank test to compare renal dysfunction by TDF or AZT first line regimen status.

The person-time (follow-up time) was accrued from date of ART initiation until the earliest of 1) the outcome – renal dysfunction/failure; 2) last documented visit by the health facility; or 3) close of the dataset at the end of December 2015.
For objective 1, to estimate the incidence of TDF-associated renal failure in patients on first line and second line ART regimens, the cumulative incidence of renal failure was calculated and expressed as the total number of persons developing renal failure per 1000 person-months of follow-up. This was then stratified by ART regimen. The outcome was defined using the DAIDS parameters (23), the abnormal renal and the eGFR low. An increase of $\geq 1.3$ in creatinine change was considered to be abnormal whereas an increase $<1.3$ was considered normal. The eGFR decrease of $\geq 10\%$ was considered abnormal, whereas the eGFR decrease of $<10\%$ was normal. (19)

For objective 2, to examine the association of ART regimen and renal failure among patients on standard first line and second line ART regimens, the Kaplan-Meier curves and the log-rank test were used to compare survival probabilities by ART regimen.

For objective 3, to examine the risk factors for renal failure among patients using regimens, bivariate and multivariate Cox-proportional hazards regression models were applied to identify risk factors for renal failure. Specifically renal dysfunction and renal failure (event of interest) was regressed against the following covariates: age, gender, WHO clinical staging, CD4 cell count.

The following socio-demographic and clinical variables were screened for inclusion into multivariate models: biological sex, age, type of first line ART regimen, body mass index, CD4 count, and WHO clinical stage at enrolment.

The variables which were identified \textit{a priori} and had a p-value $<0.20$ in bivariate analyses, were included in the multivariate regression models as potential confounders. The proportional hazard assumption was checked using graphical methods. To evaluate the robustness of these results, the univariate and multivariate analysis was repeated by applying a second definition of renal dysfunction which utilises the creatinine, high row of the DAIDS Toxicity Tables. (23)
The proportionality assumption was checked using graphical methods. Variables that were identified as a priori or significant at the \( p = 20\% \) level were considered automatically for inclusion in the final multivariate model. All \( p \)-values <0.05 were considered statistically significant.

### 3.9 Ethical Considerations

The Helsinki Declaration principles were observed throughout the life span of the research project. The ethical clearance was granted by the Swaziland Health Ethics Committee and the University of Pretoria’s Faculty of Health Sciences Research Ethics committee. Permission to access the national database was granted by the health management and information system (HMIS) department, as well as the hospital management of the RFM and MGH.

Other ethical principles, which were applied, include; that the study findings would be used for the greater benefit of the patients, the study avoided unnecessary suffering and did not cause harm (death/disability) to the study participants. The study benefits outweigh the risks of not conducting the study.

No patient identifiers were used and confidentiality of patient information and medical records was ensured at all times. The study protocol, data and all other information generated was held in strict confidence. No information concerning the study or the data was released to any unauthorized third party.
CHAPTER 4: RESULTS

The results are presented according to the objectives of the study. Between January 2010 and December 2015; 65,178 HIV-infected subjects were initiated ART in the Hhohho and Manzini regions. Among these, 1186 met the study inclusion criteria, and 67 were excluded. This left 1,119 patients for analysis.

Of the patients that were included in the study analysis, 83% (n=929) were on TDF and 17% (n=190) were on AZT. The median age was 36 years (IQR: 18 to 79 years), mean CD4 count was 194 cells/µL (95% CI: 207.61 to 228.75) and the mean GFR was 123.56, (95% CI: 121.22 to 125.92). The eGFR was normal at baseline for 81.41% (911) of the study participants.
4.1 Descriptive analysis

The baseline demographic and clinical characteristics of the 1119 study participants initiated on ART between January 2010 and December 2015 at the two hospitals are shown in Table 6.

Table 6: Descriptive analysis of participants on ART initiation of TDF-based and AZT-based regimen at MGH and RFM hospitals, 2010-2015

<table>
<thead>
<tr>
<th></th>
<th>TDF-based</th>
<th>%</th>
<th>AZT-based</th>
<th>%</th>
<th>Total</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td>n=929</td>
<td></td>
<td>n=190</td>
<td></td>
<td>N=1119</td>
<td>100</td>
</tr>
<tr>
<td>F</td>
<td>544</td>
<td>58.56%</td>
<td>147</td>
<td>77.37%</td>
<td>691</td>
<td>61.75%</td>
</tr>
<tr>
<td>M</td>
<td>385</td>
<td>41.44%</td>
<td>43</td>
<td>22.63%</td>
<td>428</td>
<td>38.25%</td>
</tr>
<tr>
<td><strong>Facility Cluster</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGH</td>
<td>458</td>
<td>49.30%</td>
<td>91</td>
<td>47.89%</td>
<td>549</td>
<td>49.06%</td>
</tr>
<tr>
<td>RFM</td>
<td>471</td>
<td>50.70%</td>
<td>99</td>
<td>52.11%</td>
<td>570</td>
<td>50.94%</td>
</tr>
<tr>
<td><strong>Age group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40 years</td>
<td>565</td>
<td>60.82%</td>
<td>126</td>
<td>66.32%</td>
<td>691</td>
<td>61.75%</td>
</tr>
<tr>
<td>&gt;40 years</td>
<td>364</td>
<td>39.18%</td>
<td>64</td>
<td>33.68%</td>
<td>428</td>
<td>38.25%</td>
</tr>
<tr>
<td><strong>Median age 36</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHO clinical stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I and II</td>
<td>628</td>
<td>67.60%</td>
<td>133</td>
<td>70.00%</td>
<td>761</td>
<td>68.01%</td>
</tr>
<tr>
<td>III and IV</td>
<td>301</td>
<td>32.40%</td>
<td>57</td>
<td>30.00%</td>
<td>358</td>
<td>31.99%</td>
</tr>
<tr>
<td><strong>BMI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Under weight (&lt;18.5)</td>
<td>95</td>
<td>10.23%</td>
<td>20</td>
<td>10.53%</td>
<td>115</td>
<td>10.28%</td>
</tr>
<tr>
<td>Normal (18.5 - 24.9)</td>
<td>424</td>
<td>45.64%</td>
<td>76</td>
<td>40.00%</td>
<td>500</td>
<td>44.68%</td>
</tr>
<tr>
<td>Over weight (25 - 30)</td>
<td>410</td>
<td>44.13%</td>
<td>94</td>
<td>49.47%</td>
<td>504</td>
<td>45.04%</td>
</tr>
<tr>
<td><strong>Median=24.45</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 count</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;100</td>
<td>251</td>
<td>27.02%</td>
<td>44</td>
<td>23.16%</td>
<td>295</td>
<td>26.36%</td>
</tr>
<tr>
<td>100-199</td>
<td>232</td>
<td>24.97%</td>
<td>49</td>
<td>25.79%</td>
<td>281</td>
<td>25.11%</td>
</tr>
<tr>
<td>200-349</td>
<td>309</td>
<td>33.26%</td>
<td>72</td>
<td>37.89%</td>
<td>281</td>
<td>34.05%</td>
</tr>
<tr>
<td>350+</td>
<td>137</td>
<td>14.75%</td>
<td>25</td>
<td>13.16%</td>
<td>162</td>
<td>14.48%</td>
</tr>
<tr>
<td><strong>Median CD4 count = 194</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GFR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>757</td>
<td>81.49%</td>
<td>154</td>
<td>81.05%</td>
<td>911</td>
<td>81.41%</td>
</tr>
<tr>
<td>Mild</td>
<td>151</td>
<td>16.25%</td>
<td>30</td>
<td>15.79%</td>
<td>181</td>
<td>16.18%</td>
</tr>
<tr>
<td>Moderate</td>
<td>21</td>
<td>2.26%</td>
<td>6</td>
<td>3.16%</td>
<td>27</td>
<td>2.41%</td>
</tr>
<tr>
<td><strong>Mean GFR= 123.57</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TDF: Tenofovir
AZT: Zidovudine
F: Female
M: Male
MGH: Mbabane Government Hospital
RFM: Raleigh Fitkin Memorial Hospital
BMI: Body Mass index
GFR: Glomerular filtration rate
Of the study participants enrolled, 691 (61.75%) were female, 428 (38.25%) were male. Those aged less than 40 years were 691 (61.75%). Participants who had early disease (WHO clinical stage I and II) were 761 (68.01%) and those with advanced HIV disease (WHO stage III and IV) were 358 (31.99%). At enrollment 500 (44.68%) participants had a normal BMI whereas 115 (10.28%) and 504 (45.04%) were underweight and overweight, respectively.

The GFR was normal in 911 (81.41%) of the study participants and it was mild in 181 (16.18%) and moderate in 27 (2.41%) of the participants. Of note, is that none of the participants had severe GFR nor were in renal failure at ART initiation (that is, failure due to sole HIV disease).

4.2 Outcome variable definition

The outcome variable, renal failure and dysfunction, was measured as a proxy by inferring a regimen modification from a TDF-based regimen to either ABC or AZT based regimen and where either in first line or second line ART regimen.

The outcome was measured by the change in the eGFR from the baseline, which is an abnormal GFR. The change had to be \( \geq 10\% \) decrease from each participant’s baseline GFR, based on the division of AIDS (DAIDS) table for grading the severity of adults and pediatric adverse events. An abnormal GFR was graded as moderate, severe or potentially life-threatening. (28)

The study participants with an abnormal eGFR or a \( \geq 10\% \) decrease from the baseline comprised 11.26% (126) of the entire cohort.
4.3 Overall follow-up time

The overall median follow-up time was 6.72 months (IQR: 0.03 to 81.61) and total person-time was 15,579 person-months (95% CI: 6.79 to 9.63).

![Kaplan-Meier curve: overall follow-up time (months)](image)

The overall incidence rate for abnormal GFR was 8.1 per 1000 person-months and the total 15,579 person-months. The larger proportion of participants (848) developed TDF-associated nephrotoxicity during the first 18-month follow-up period.

4.4 Incidence rate

The outcome was defined using the DAIDS parameters, the abnormal renal and the eGFR low.\(^{(28)}\)

4.4.1 Incidence by outcome using abnormal renal function

The overall incidence rate of failure was 4.4 per 1000 person-months and the total person-months was 14,853 (95%CI: 3.43 to 5.58) during the follow-up period.
The incidence rate of TDF-associated nephrotoxicity was 5.1 per 1000 person-months (95%CI: 3.94 to 6.72) and 10499 total person-months. Whereas the incidence rate of abnormal renal function due to non-use of TDF (AZT) was 2.5 per 1000 person-months (95%CI: 1.40 to 4.56) and 4,355 total person-months.

![Figure 5: Kaplan-Meier curve and Log-rank test for main exposure (TDF versus AZT), by abnormal renal function (creatinine) of study Participants at MGH and RFM hospital, 2010-2015](image)

The incidence rate of abnormal renal function among those on TDF was about two times higher than those on the non-TDF regimens.

4.4.2 Incidence by outcome using eGFR
The overall incidence rate for abnormal eGFR was 8.1 per 1000 person-months and the total person-months 15579 (95% CI: 6.79 to 9.63) during the follow-up period.
The incidence rate of TDF associated nephrotoxicity was 9.44 per 1000 person-months (95%CI: 7.79 to 11.44) and 11022 total person-months. The incidence rate of abnormal renal function due to non-use of TDF (AZT) was 4.83 per 1000 person-months (95%CI: 3.18 to 7.33) and 4557 total person-months.

Figure 6: Kaplan-Meier curves and Log-rank test for main exposure (TDF versus AZT) by abnormal eGFR of study Participants at MGH and RFM hospital, 2010-2015

The incidence rate of abnormal renal function (low eGFR) among those on TDF was about two times higher than that of TDF non-use.
4.5 Univariate analysis

The covariates: TDF versus AZT, sex, age, WHO stage, BMI, gender and CD4 cell count were analysed. Age, BMI and CD4 cell count were analysed both as categorical variables and as continuous variables to explore the effect they would have on renal dysfunction using the eGFR.

Table 7: The univariate analysis by covariates: sex, age, WHO stage, BMI, CD4 cell count

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Hazard Ratio</th>
<th>95%CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AZT</strong></td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TDF</strong></td>
<td>2.08</td>
<td>1.27 - 3.40</td>
<td>0.003*</td>
</tr>
<tr>
<td><strong>Sex:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.35</td>
<td>0.94 - 1.93</td>
<td>0.099</td>
</tr>
<tr>
<td><strong>Age:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40 years</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;40 years</td>
<td>1.45</td>
<td>0.81 - 1.63</td>
<td>0.450</td>
</tr>
<tr>
<td>All ages</td>
<td>1.00</td>
<td>0.99 - 1.02</td>
<td>0.664</td>
</tr>
<tr>
<td><strong>WHO clinical stage:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I and II</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III and IV</td>
<td>0.96</td>
<td>0.66 - 1.39</td>
<td>0.823</td>
</tr>
<tr>
<td><strong>BMI:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>0.84</td>
<td>0.46 - 1.56</td>
<td>0.597</td>
</tr>
<tr>
<td>Obese</td>
<td>1.07</td>
<td>0.59 - 1.94</td>
<td>0.833</td>
</tr>
<tr>
<td>All BMI</td>
<td>1.03</td>
<td>0.99 - 1.06</td>
<td>0.103</td>
</tr>
<tr>
<td><strong>CD4:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;100</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100-199</td>
<td>1.19</td>
<td>0.74 - 1.90</td>
<td>0.476</td>
</tr>
<tr>
<td>200-349</td>
<td>0.90</td>
<td>0.56 - 1.45</td>
<td>0.671</td>
</tr>
<tr>
<td>350+</td>
<td>0.84</td>
<td>0.47 - 1.50</td>
<td>0.551</td>
</tr>
<tr>
<td>All CD4 cell counts</td>
<td>1.00</td>
<td>0.99 - 1.00</td>
<td>0.171</td>
</tr>
</tbody>
</table>

*p-value is <0.05 (statistically significant)

TDF: Tenofovir
AZT: Zidovudine
BMI: Body Mass index

The use of a TDF-based regimen compared to that of an AZT-based regimen was associated with 2-fold increased hazard of failure during the follow-up period (HR: 2.08, 95%CI 1.27 to 3.40, p=0.003).
Similarly, being male compared to female sex (HR 1.35, 95%CI 0.94 to 1.93), p=0.099) and being older (HR 1.45, 95%CI 0.81 to 1.63) showed a trend towards increased hazard of renal dysfunction (eGFR) during the follow-up period. Although these estimates were imprecise, they did not reach statistical significance.

4.6 Multivariate Analysis

As seen from Table 7 above, the use of TDF was significant in the univariate analysis, although the other listed covariates were not statistically significant. All covariates were analysed in order to explore the effect they would have on the renal dysfunction using the eGFR.

Table 8: The multivariate analysis by covariates: sex, age, WHO stage, BMI, CD4 cell count

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDF use</td>
<td>2.04</td>
<td>1.24 - 3.35</td>
<td>0.005*</td>
</tr>
<tr>
<td>Sex</td>
<td>1.28</td>
<td>0.87 - 1.88</td>
<td>0.203</td>
</tr>
<tr>
<td>Age</td>
<td>1.07</td>
<td>0.75 - 1.53</td>
<td>0.725</td>
</tr>
<tr>
<td>WHO clinical stage</td>
<td>0.89</td>
<td>0.60 - 1.33</td>
<td>0.573</td>
</tr>
<tr>
<td>BMI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>0.80</td>
<td>0.43 - 1.48</td>
<td>0.473</td>
</tr>
<tr>
<td>Obese</td>
<td>1.08</td>
<td>0.58 - 2.02</td>
<td>0.809</td>
</tr>
<tr>
<td>CD4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100-199</td>
<td>1.20</td>
<td>0.74 - 1.93</td>
<td>0.462</td>
</tr>
<tr>
<td>200-349</td>
<td>0.90</td>
<td>0.55 - 1.47</td>
<td>0.672</td>
</tr>
<tr>
<td>350+</td>
<td>0.85</td>
<td>0.46 - 1.55</td>
<td>0.594</td>
</tr>
</tbody>
</table>

*p-value<0.05 (statistically significant)

The multivariate analysis (Table 8) showed that the exposure to TDF had a 2 fold (times) increased risk of an abnormal renal function (eGFR) during the follow-up period (p-value=0.005), after adjusting for sex, age, WHO clinical staging, BMI and CD4 cell count. The listed covariates had p-values >0.05 and were therefore, not statistically significant.
CHAPTER 5: DISCUSSION

This retrospective data analysis explored the incidence and risk factors of nephropathy associated with TDF use among HIV-infected adults exposed to TDF and were active on antiretroviral therapy in Swaziland, during the period 2010-2015.

5.1 Descriptive Analysis

A total of 1,186 participants met the study inclusion criteria and 67 participants were excluded from the analysis. The 67 participants were excluded because only 2 participants were on second line at the start of the study period which is a small number, and 65 study participants had an ART start date that was after the last ART date.

In the study, 83% (n=929) were on TDF and 17% were on AZT (n=190). The median age was 36 years (IQR: 18 to 79 years), mean CD4 count 194 cells/µL (95% CI: 207.61 to 228.75) and the mean baseline eGFR was 123.56, (95% CI: 121.22 to 125.92). The eGFR was normal at baseline for 81.41% (911) of the study participants and it was mild in 181 (16.18%) and moderate in 27 (2.41%) of the participants.

Of note, is that none of the participants had severe GFR nor were in renal failure at during ART initiation (that is, failure due to sole HIV disease). This is similar and represents the demographics of the population on ART in Swaziland and is comparable to other African countries and the sub-Saharan region.\(^{29,30,31}\)

5.2 Overall follow-up time

The median follow-up time was 6.72 months (IQR: 0.03 to 81.61) and total person-time was 15,579 person-months (95% CI: 6.79 to 9.63), which was within the mean follow-up range found in other studies (range: 0.3-9.7 years).\(^{32,20,26}\)
5.3 Incidence rate of abnormal eGFR

This retrospective analysis showed that the overall incidence rate for abnormal eGFR (eGFR, Low) was 8.1 per 1000 person-months and the 15,579 total person-months for the study participants had a >10% change from the baseline eGFR. Conversely, this was noted when using the variable, change in creatinine. The eGFR is the more robust variable than creatinine. Both the eGFR and creatinine changes are suggestive of the documented nephrotoxic effects of TDF during follow-up time.\(^{(15)(16)(34)}\)

The frequency of the occurrence of the outcome of interest (TDF-associated nephrotoxic adverse effect) was in 11.26% of the study participants. The frequency in this study is higher than the 10.8%, 8.16%, 6.3% and 2.4%, observed in other studies.\(^{(11)(33)(35)(36)}\) However, it still remains lower than what is documented is some studies which have demonstrated that tubular dysfunction with TDF occurs in 17–22% of Tenofovir-treated patients; as opposed to 6% and 12% of ART-treated or naive HIV patients, respectively.\(^{(37)(34)}\)

A Zambian study found that the point prevalence of renal dysfunction among HIV-positive adults exposed to TDF was 18.6% at 18 months follow-up.\(^{(29)}\) However, a Zimbabwean study, noted the adverse events frequency of TDF at 39%.\(^{(36)}\) In these studies, none of the study participants developed end-stage renal failure.

Our study further analysed the incidence rate by the exposure status, TDF and AZT. Notably, the TDF-associated nephrotoxicity was 9.44 per 1000 person-months (95% CI: 7.79 to 11.44) and 11022 total person-months. The incidence rate of abnormal renal function due to non-use of TDF (AZT) was 4.83 per 1000 person-months (95% CI: 3.18 to 7.33) and 4557 total person-month.

Our findings concur with the pool of evidence from other studies, that exposure to TDF is nephrotoxic, since the participants exposed to TDF showed a two-fold increased risk of an abnormal renal function during the follow-up period.\(^{(38),(39)}\) A published editorial commentary affirms that TDF users with a baseline normal eGFR or mild kidney disease were 2-3 times more likely to progress to advanced kidney disease than their non-TDF counterparts.\(^{(30)}\)
5.4 Risk factors associated with Tenofovir associated renal dysfunction

In this cohort the exposure to TDF had a significant association with the development of renal dysfunction, although there was no renal failure. This study also set out to determine the associated risk factors for TDF associated renal dysfunction in Swaziland, however there was no confirmed association between the assessed covariates of sex, age, WHO clinical staging, BMI and CD4 cell count and developing renal dysfunction (p-value>0.05).

Some studies have confirmed that in addition to the above listed covariates/risk factors, other predisposing factors include elevated baseline serum creatinine, pre-existing decrease in kidney function, concomitant nephrotoxic medications, gender, presence of hypertension, high BMI, low body weight, advanced age, use of TDF with microalbuminuria, as well as the duration of TDF treatment.\(^{(36)(40)(41)}\)

The only factor associated with renal dysfunction in this study was TDF use which is similar to the one study conducted in Ghana\(^{(42)}\). This was evident in both the univariate and multivariate analyses.

5.5 Economic estimation of the cost of reversing the TDF associated renal dysfunction

The TDF-associated renal dysfunction or nephrotoxicity has a dire economic effect since patients under routine clinical monitoring need to undergo renal dialysis to recover from the toxic effects of TDF.\(^{(17)(37)(43)}\) It is routinely documented in the patient registers in the dialysis units of the two hospitals (MGH and RFM), that patients can take from 3 days to 12 weeks to recover from the TDF nephrotoxic effects at a cost of Emalangeni (SZL) 1,500.00 or US Dollar (USD) 125.00 per dialysis session.

This cost is borne by the government whereas SZL20.00 or USD 1.60 is borne as an out-of-pocket expense by the patients towards hospital stay. Other dire financial consequences include the loss of household income while the patient recovers.
5.6 HIV and HBV co-infection

Although TDF is an effective and widely used treatment for Hepatitis B virus (HBV) infection, most cases of TDF-associated nephrotoxicity have been described in patients co-infected with HIV rather than sole HBV.\(^{(41)}\) TDF is the drug of choice for the management of HBV and its use is expected to increase so will the cases of the associated renal dysfunction. New drugs indicated for the management of HIV and/or HBV with a less side-effect profile have been introduced in the market.

5.6.1 Tenofovir Alafenamide

Tenofovir Alafenamide (TAF) is a nucleotide reverse transcriptase inhibitor and the next-generation Tenofovir prodrug, with a distinctive metabolism intended to maximize antiviral potency and clinical safety. It is indicated for use in the treatment of HIV infection and chronic hepatitis B. TAF is more stable in plasma which results in higher intracellular levels leading to increased distribution to tissues of lymphatic origin when compared with Tenofovir.

The Tenofovir in TAF is actively transported from the blood into renal proximal tubule cells by anion transporters OAT1 and OAT3. The reduction in plasma exposures results in lower concentrations in proximal tubular cells and less nephrotoxicity.\(^{(44)(45)(46)}\)

TAF has been demonstrated to have improved clinical efficacy, long-term greater antiviral efficacy, a higher barrier to resistance and an improved safety profile relative to TDF. Unlike TDF, which should be avoided or dose-adjusted in patients with renal dysfunction or estimated creatinine clearance (CrCl) < 80 mL/min, TAF-containing regimens appear to be safe and are FDA-approved for use in patients with estimated CrCl as low as 30 mL/min.\(^{(44)(45)(46)}\)

However the evidence on safety and efficacy in pregnancy and TB-co-infection of TAF has prevented its inclusion into the WHO guidelines and the WHO Essential Medicines List.\(^{(45)(47)}\)

In a large randomized trial, tests done on bone and renal function, significantly favoured the switch to TAF. The trial showed that TAF has a better side-effect profile and proved to be more superior than TDF in maintaining virologic suppression in patients who switch to TAF. Hence, TAF was proved to be safe and well-tolerated.\(^{(46)(48)}\) On the contrary, a systematic
review did not confirm any difference in efficacy between the two formulations on HIV RNA suppression, clinical adverse events and discontinuation due to renal or bone side effects.\textsuperscript{(49)}
CHAPTER 6: STRENGTHS AND WEAKNESSES (LIMITATIONS)

6.1 Strengths

6.1.1 To our knowledge, this is the first study to be conducted which has examined TDF-associated nephrotoxicity in Swaziland.

6.1.2 The availability of the electronic data medical clinical records from the national data base made it possible to have study participants with follow-up results over the study period of 2010-2015.

6.2.3 The study was conducted in two of the densely populated regions and two of the high volume, public serving hospitals in Swaziland using the nationally defined standard of care, therefore the results of the study are generalizable to the HIV-infected population on first line ART.

6.2 Limitations

6.2.1 The secondary data obtained from the National ART data base for MGH and RFM were incomplete. Hence, not all the key variables were completed e.g. co-morbidities, nor was the data base designed for operative research purposes.

6.2.2 HIV infection in itself causes renal pathology and differentiation of the aetiology was not done. The study excluded those patients who may have died before the study which led survivorship bias.

6.2.3 Despite the effort to minimise selection bias through the systemic sampling method, it can not be entirely excluded. Possible misclassification bias was minimised by blinding from exposure/outcome status.

6.2.4 Potential confounders include age, HIV disease and co-morbid chronic conditions (such as hypertension and diabetes mellitus), which can independently cause renal dysfunction.
6.2.5 Since this study was not a randomized clinical trial there were concerns with attribution. While the study was able to associate TDF with reduced renal function; it cannot, however, attribute that to TDF in isolation because there are other likely but unmeasured confounders (for example, pharmacokinetics, pharmacogenetics, host immune response differences).
CHAPTER 7: CONCLUSION AND RECOMMENDATIONS

Although TDF is safe and effective in HIV management, it is associated with 2 fold (times) increased risk of an abnormal renal function during the follow-up period compared to those who initiated on AZT. This is low compared to documented literature. Other variables (sex, age, WHO stage, BMI, CD4 cell count) showed no associated risk in the study participants.

Most worthwhile is for the Ministry of Health in Swaziland to start to intensify renal function monitoring of patients on TDF and start to consider and plan for the introduction of Tenofovir alafenamide (TAF) for the benefit of patients who experience the adverse-events which are associated with TDF. The high-resource countries in Asia have recommended that TDF should be discontinued early for patients at risk of developing TDF-associated nephrotoxicity and in patients with chronic kidney disease and replace it with its prodrug TAF.\(^{(40)}\)

### 7.1 Tenofovir Alafenamide (TAF)

Tenofovir alafenamide (TAF), an oral prodrug of TDF, is now included as a component of several recommended first-line antiretroviral therapy regimens. These recommendations are based on data from comparative trials demonstrating that TAF-containing regimens are as effective in achieving or maintaining virologic suppression as TDF-containing regimens and is effective for HBV treatment but with more favorable effects on markers of renal and bone health. Patients being treated for HIV and or HBV would benefit from TAF and experience less or no side effects compared to TDF. However, the cost-effectiveness of replacing TDF with TAF containing regimen in resource limited settings remains unclear.

### 7.2 Database Redesign

The current Ministry of Health’s HMIS national database has to be designed, be tailored for research purposes and be monitored for quality. This can be achieved by the engagement and involvement of the departments that have an interest, a mandate and vast experience with the management of national datasets and databases.
These include, but are not limited to the Strategic Information Unit, the Ministry of Information Communication and Technology as well the Royal Science and Technology Park.

7.3 Review of HIV Management Guidelines

Now that the burden of TDF-associated nephropathy has been revealed and quantified by this study and it supports the Ministry of Health’s decision to continue to use TDF the HIV management. The SNAP working closely with the National Health Laboratory Services (NHLS) will need to actively collaborate, advocate and ensure nationwide access to laboratory monitoring services for all patients, particularly those on TDF, as well as to ensure that the forecasting and quantification of renal function tests laboratory reagents is done. This will assist and ensure accurate patient monitoring and appropriate management in all health care facilities in the country. It is imperative that routine monitoring of all patients using TDF should be performed.\(^{(41)}\)

7.4 Further Research

There is a need to also conduct further studies using longitudinal data from clinical monitoring visits in order to examine the renal function over time while patients are on TDF, and to conduct a more comprehensive economic evaluation on the effects TDF associated renal dysfunction or nephrotoxicity. It would be beneficial to also conduct studies on the use of TDF both in HBV-infected non-HIV patients and in HIV/HBV co-infected patients, so as to add to the body of evidence both nationally and internationally.
REFERENCES


30. Estrella MM, Moosa MR, Nachega JB. Risks and Bene fi ts of Tenofovir in the Context


42. Fs S, Es K, Al O. Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana. BMC Nephrol [Internet]. 2015;16:195. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=awn&AN=26627687&site=ehost-live&scope=site%0D%0A


47. World Health Organization. Comments on EML application: tenofovir alafenamide for HBV infection [Internet]. GENEVA; 2018. Available from: http://www.who.int/selection_medicines/committees/expert/21/applications/Tenofovir_alafenamide_HIV.pdf?ua=1

ANNEXES

Annex 1: Permission to access records approval

Permission to access Records / Files / Data base at the Mbabane Government Hospital

To: Chief Executive Officer/Information Officer
    Mbabane Government Hospital
    Dr P. S. Malafiyana

From: The Investigator
    World Health Organization-Swaziland
    Dr Sithebile Dlamini-Nqeketo

Re: Permission to do research at Mbabane Government Hospital

Dr Sithebile Dlamini-Nqeketo is a researcher working at the World Health Organization-Swaziland, TB/HIV/HEPATITIS Unit. I am requesting permission to conduct a study on the Mbabane Government Hospital grounds that involves access to patient records.

The request is lodged with you in terms of the requirements of the Promotion of Access to Information Act, No. 2 of 2000. The title of the study is: The epidemiology of Tenofovir-associated renal failure in patients on antiretroviral triple regimen in Swaziland.

The researcher requests access to the following information:


We intend to publish the findings of the study in a professional journal and/or at professional meeting like symposia, congresses, or other meetings of such a nature.

We intend to protect the personal identity of the patients by assigning each patient a random code number.

We undertake not to proceed with the study until we have received approval from the Faculty of Health Sciences Research Ethics Committee, University of Pretoria.

Yours sincerely,

[Signature of the Principle Investigator]

Permission to do the research study at this hospital and to access the information as requested is hereby approved.

Chief Executive Officer

Mbabane Government Hospital

[Signature of the CEO]

12 OCT 2016

[Stamp: MABABANE GOVERNMENT HOSPITAL]
Permission to access Records / Files / Data base at the Raleigh Fitkins Memorial (RFM) Hospital

To: Chief Executive Officer/Information Officer
Raleigh Fitkins Memorial Hospital
Dr RAYMOND RITCHOND

From: The Investigator
World Health Organization-Swaziland
Dr Sithembile Dlamini-Nqeketo

Re: Permission to do research at Raleigh Fitkins Memorial (RFM) Hospital

Dr Sithembile Dlamini-Nqeketo is a researcher working at the World Health Organization- Swaziland, TB/HIV/HEPATITIS Unit. I am requesting permission to conduct a study on the Raleigh Fitkins Memorial Hospital grounds that involves access to patient records.

The request is lodged with you in terms of the requirements of the Promotion of Access to Information Act. No. 2 of 2000.

The title of the study is: The epidemiology of Tenofovir-associated renal failure in patients on antiretroviral triple regimen in Swaziland.

The researcher requests access to the following information:


We intend to publish the findings of the study in a professional journal and/or at professional meeting like symposia, congresses, or other meetings of such a nature.

We intend to protect the personal identity of the patients by assigning each patient a random code number.

We undertake not to proceed with the study until we have received approval from the Faculty of Health Sciences Research Ethics Committee, University of Pretoria.

Yours sincerely

[Signature]

Signature of the Principle Investigator

Permission to do the research study at this hospital and to access the information as requested is hereby approved.

Chief Executive Officer

Raleigh Fitkins Memorial Hospital
Dr RAYMOND RITCHOND

[Signature]

Signature of the CEO

Hospital Official Stamp
Annex 2: Data collection form: TDF associated nephrotoxicity and risk factors

Study Site: …………………. ART Clinic/hospital: ………………….

1. Demographic variables

1.1. Date of birth: ……………….

1.2. Sex (X): Male…………… Female……………

2. ART Eligibility criteria and Baseline Clinical Information

2.1. Date of initiation of ART:……../……../……….

2.2 Clinical parameters | Result
--- | ---
Patient BMI (Kg/Ht$^2$) | 
CD4 cell count (cells/mm$^3$) | 
WHO clinical staging(25) (at initiation) | 
WHO clinical staging (Last visit) | 
Listed Co-morbidities | 
Baseline serum creatinine | 
Date of baseline serum creatinine | 
Follow-up serum creatinine | 
Date of follow-up serum creatinine | 
Baseline Renal status (Normal/ abnormal) | 
Final Renal status (Normal/ abnormal) | 
Date of last clinic visit | 

2.3 Initial 1$^\text{st}$ line ART Regimen: ............................................

2.4 Second line ART Regimen .................................
3. Management of TDF-associated nephrotoxicity:

3.1 Date of ARV substitution: .................................................................

3.2 Reason for ARV substitution: ...........................................................

3.3 Current ART Regimen ........................................................................

3.4 Last CD4⁺ count (cells/mm³).........................................................
Annex 4: Ethical approval reference no: 428/2016 for amendment of protocol

The Research Ethics Committee, Faculty of Health Sciences, University of Pretoria complies with ICH-GCP guidelines and has US Federal wide Assurance.  
- IRB: 0000000697 Approved 22 May 2012 and Expires 22/05/2020. 

Faculty of Health Sciences Research Ethics Committee  
31/05/2018

Approval Certificate  
Amendment  
(to be read in conjunction with the main approval certificate)

Ethics Reference No: 428/2016

Title: THE EPIDEMIOLOGY OF TENOFOVIR-ASSOCIATED RENAL FAILURE IN PATIENTS ON ANTIRETROVIRAL THERAPY IN SWAZILAND

Dear Dr Sthembile Dilumini-Nqeketo

The Amendment as described in your documents specified in your cover letter dated 26/02/2018 received on 30/05/2018 was approved by the Faculty of Health Sciences Research Ethics Committee on its quarterly meeting of 30/05/2018.

Please note the following about your ethics amendment:
- Please remember to use your protocol number (428/2016) on any documents or correspondence with the Research Ethics Committee regarding your research.
- Please note that the Research Ethics Committee may ask further questions, seek additional information, require further modification, or monitor the conduct of your research.

Ethics amendment is subject to the following:
- The ethics approval is conditional on the receipt of 8 monthly written Progress Reports, and
- The ethics approval is conditional on the research being conducted as stipulated by the details of all documents submitted to the Committee. In the event that a further need arises to change who the investigators are, the methods or any other aspect, such changes must be submitted as an Amendment for approval by the Committee.

We wish you the best with your research.

Yours sincerely,

Dr R Samuels, MSc (UB); MMed (Int); MPhil (Med); PhD
Deputy Chairperson of the Faculty of Health Sciences Research Ethics Committee, University of Pretoria

The Faculty of Health Sciences Research Ethics Committee complies with the SA National Act 31 of 2003 as it pertains to health research and the United States Code of Federal Regulations Title 45 and 46. This committee abides by the ethical norms and principles for research, established by the Declaration of Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes, Second Edition 2015 (Department of Health).

Tel 012 356 3084  deepika.bethani@up.ac.za  http://www.up.ac.za/healthethics  
Private Bag X323, Arcadia, 0007 – Tswetlopele Building, Level 4, Room 90 / 91, 31 Bophelo Road, Gezina, Pretoria
Annex 5: WHO clinical staging of HIV disease in adults, adolescents and children

Annex 5. WHO clinical staging of HIV disease in adults, adolescents and children


<table>
<thead>
<tr>
<th>Adults and adolescents*</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical stage 1</strong></td>
<td></td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>Asymptomatic</td>
</tr>
<tr>
<td>Persistent generalized lymphadenopathy</td>
<td>Persistent generalized lymphadenopathy</td>
</tr>
<tr>
<td><strong>Clinical stage 2</strong></td>
<td></td>
</tr>
<tr>
<td>Moderate unexplained weight loss (&lt;10% of presumed or measured body weight)</td>
<td>Unexplained persistent hepatosplenomegaly</td>
</tr>
<tr>
<td>Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media, pharyngitis)</td>
<td>Recurrent or chronic upper respiratory tract infections (otitis media, otorrhoea, sinusitis, tonsillitis)</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>Herpes zoster</td>
</tr>
<tr>
<td>Angular cheilitis</td>
<td>Lineal gingival erythema</td>
</tr>
<tr>
<td>Recurrent oral ulceration</td>
<td>Recurrent oral ulceration</td>
</tr>
<tr>
<td>Papular pruritic eruption</td>
<td>Papular pruritic eruption</td>
</tr>
<tr>
<td>Fungal nail infections</td>
<td>Fungal nail infections</td>
</tr>
<tr>
<td>Seborrhoeic dermatitis</td>
<td>Extensive wart virus infection</td>
</tr>
<tr>
<td></td>
<td>Extensive molluscum contagiosum</td>
</tr>
<tr>
<td></td>
<td>Unexplained persistent parotid enlargement</td>
</tr>
<tr>
<td><strong>Clinical stage 3</strong></td>
<td></td>
</tr>
<tr>
<td>Unexplained severe weight loss (&gt;10% of presumed or measured body weight)</td>
<td>Unexplained moderate malnutrition&lt;sup&gt;b&lt;/sup&gt; not adequately responding to standard therapy</td>
</tr>
<tr>
<td>Unexplained chronic diarrhoea for longer than 1 month</td>
<td>Unexplained persistent diarrhoea (14 days or more)</td>
</tr>
<tr>
<td>Unexplained persistent fever (intermittent or constant for longer than 1 month)</td>
<td>Unexplained persistent fever (above 37.5°C, intermittent or constant, for longer than one month)</td>
</tr>
<tr>
<td>Persistent oral candidiasis</td>
<td>Persistent oral candidiasis (after first 6 weeks of life)</td>
</tr>
<tr>
<td>Oral hairy leukoplakia</td>
<td>Oral hairy leukoplakia</td>
</tr>
<tr>
<td>Pulmonary tuberculosis</td>
<td>Lymph node tuberculosis</td>
</tr>
<tr>
<td>Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, bacteraemia)</td>
<td>Pulmonary tuberculosis</td>
</tr>
<tr>
<td>Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis</td>
<td>Severe recurrent bacterial pneumonia</td>
</tr>
<tr>
<td>Unexplained anaemia (&lt;8 g/dl), neutropaenia (&lt;0.5 x 10⁹/l) and/or chronic thrombocytopenia (&lt;50 x 10⁹/l)</td>
<td>Acute necrotizing ulcerative gingivitis or periodontitis</td>
</tr>
<tr>
<td></td>
<td>Unexplained anaemia (&lt;8 g/dl), neutropaenia (&lt;0.5 x 10⁹/l) or chronic thrombocytopenia (&lt;50 x 10⁹/l)</td>
</tr>
<tr>
<td>Adults and adolescents</td>
<td>Children</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Clinical stage 3</strong></td>
<td>Symptomatic lymphoid interstitial pneumonitis</td>
</tr>
<tr>
<td>Chronic HIV-associated lung disease, including bronchiectasis</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical stage 4</strong></td>
<td>Unexplained severe wasting, stunting or severe malnutrition not responding to standard therapy</td>
</tr>
<tr>
<td>HIV wasting syndrome</td>
<td><em>Pneumocystis (jiroveci) pneumonia</em></td>
</tr>
<tr>
<td>Recurrent severe bacterial pneumonia</td>
<td><em>Pneumocystis (jiroveci) pneumonia</em></td>
</tr>
<tr>
<td>Chronic herpes simplex infection (orolabial, genital or anorectal of more than 1 month's duration or visceral at any site)</td>
<td>Recurrent severe bacterial infections (such as empyema, pyomyositis, bone or joint infection, meningitis, but excluding pneumonia)</td>
</tr>
<tr>
<td>Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)</td>
<td>Chronic herpes simplex infection (orolabial or cutaneous of more than 1 month's duration or visceral at any site)</td>
</tr>
<tr>
<td>Extrapulmonary tuberculosis</td>
<td>Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td>Extrapulmonary tuberculosis</td>
</tr>
<tr>
<td>Cytomegalovirus infection (retinitis or infection of other organs)</td>
<td>Kaposi sarcoma</td>
</tr>
<tr>
<td>Central nervous system toxoplasmosis</td>
<td>Cytomegalovirus infection (retinitis or infection of other organs with onset at age more than 1 month)</td>
</tr>
<tr>
<td>HIV encephalopathy</td>
<td>Central nervous system toxoplasmosis (after the neonatal period)</td>
</tr>
<tr>
<td>Extrapulmonary cryptococcosis, including meningitis</td>
<td>HIV encephalopathy</td>
</tr>
<tr>
<td>Disseminated nontuberculous mycobacterial infection</td>
<td>Extrapulmonary cryptococcosis, including meningitis</td>
</tr>
<tr>
<td>Progressive multifocal leukoencephalopathy</td>
<td>Disseminated nontuberculous mycobacterial infection</td>
</tr>
<tr>
<td>Chronic cryptosporidiosis</td>
<td>Progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td>Chronic isosporiasis</td>
<td>Chronic cryptosporidiosis (with diarrhoea)</td>
</tr>
<tr>
<td>Disseminated mycosis (extrapulmonary histoplasmosis, coccidioidomycosis)</td>
<td>Chronic isosporiasis</td>
</tr>
<tr>
<td>Lymphoma (cerebral or B-cell non-Hodgkin)</td>
<td>Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidioidomycosis, penicilliosis)</td>
</tr>
<tr>
<td>Symptomatic HIV-associated nephropathy or cardiomyopathy</td>
<td>Cerebral or B-cell non-Hodgkin lymphoma</td>
</tr>
<tr>
<td>Recurrent septicaemia (including nontyphoidal <em>Salmonella</em>)</td>
<td>HIV-associated nephropathy or cardiomyopathy</td>
</tr>
<tr>
<td>Invasive cervical carcinoma</td>
<td>Atypical disseminated leishmaniasis</td>
</tr>
</tbody>
</table>

---

*In the development of this table, adolescents were defined as 15 years or older. For those aged less than 15 years, the clinical staging for children should be used.*

*For children younger than 5 years, moderate malnutrition is defined as weight-for-height <-2 z-score or mid-upper arm circumference a115 mm to <125 mm.*

*Some additional specific conditions can be included in regional classifications, such as penicilliosis in Asia, HIV-associated rectovaginal fistula in southern Africa and reactivation of trypanosomiasis in Latin America.*

*For children younger than 5 years of age, severe wasting is defined as weight-for-height <-3 z-score; stunting is defined as length-for-age/height-for-age <-2 z-score; and severe acute malnutrition is either weight for height <-3 z-score or mid-upper arm circumference <115 mm or the presence of oedema.*